Novocure Israel Ltd
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$2.9M
Doctors Paid
10
Transactions
79
2023 Total
$138,036
Payment Breakdown by Category
Research$2.6M (91.6%)
Food & Beverage$798.37 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.6M | 57 | 91.6% |
| Grant | $240,000 | 8 | 8.4% |
| Food and Beverage | $798.37 | 14 | 0.0% |
Payments by Type
Research
$2.6M
57 transactions
General
$240,798
22 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Project 2 - Inpact of TTFields on Glioma-infrlt | $324,176 | 0 | 4 |
| Project 1- Mechanism of Resistance | $305,510 | 0 | 3 |
| Investigating Impact of TTFields on Chemotherapies and on Hypoxic Phenotypes | $240,000 | 0 | 8 |
| Tumor Treating Fields Research Grant | $202,500 | 0 | 2 |
| Explore potential synergy between the combination of radiation exposure and tumor-treatment field (TTF) technology, to discern mechanisms of TTF and TTF plus radiation response, and to identify from a battery of tumor cell lines molecular markers for those cell lines that are most and least responsive to TTF and TTF plus radiation. | $199,052 | 0 | 1 |
| High Resolution Magnetic Resonance Imaging (MRS) to evaluate therapeutic response to Novo-TTF in brain tumors | $151,075 | 0 | 7 |
| CAS Protocol EF- A Prospective Phase II Trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with recurrent Glioblastoma | $151,055 | 0 | 4 |
| A Phase 2, Multi-center, Single arm, Histologically Controlled Study Testing the Combination of TTFields and Pulsed Bevacizumab Treatment in Patients with Bevacizumab-refractory Recurrent Glioblastoma | $136,640 | 0 | 3 |
| Impact of TTFields on Glioma-infiltrating immune cells. | $125,000 | 0 | 1 |
| MTA - Combining Tumor Treating Fields with Radiation | $105,724 | 0 | 1 |
| MTA Project 1- Mechanism of Resistance | $98,624 | 0 | 1 |
| High resolution MRI and MRS to evaluate therapeutic response to Novo-TTF in brain tumors | $96,072 | 0 | 3 |
| Multimodal Imaging of Metabolic Changes During NocoTTF Treatment in Patient with Recurrent Glioblastoma. | $88,722 | 0 | 4 |
| Optimization of TTF Parameters in 3D MulticellularSperoid Models | $60,165 | 0 | 1 |
| Pre-Clinical evaluation of combing non-ioninzing radiation generated by tumor treating fields with standard and investigational treatments of gliomas | $55,892 | 0 | 2 |
| A Prospective Phase II Trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with recurrent Glioblastoma | $53,578 | 0 | 1 |
| A Phase II, Multi-Center, Single arm, Historically Controlled Study Testing the Combination of TTFields and Pulsed Bevacizumab Treatment in Patients with Bevacizumab-refractory Recurrent Glioblastoma. | $37,272 | 0 | 1 |
| A Phase II Study of Novo TTF-100A System in Combination with Bevacizumab (BEV) and Temozolomide (TMZ) in Patients with Newly Diagnosed Unresectable Glioblastoma (GBM) | $36,999 | 0 | 1 |
| High resolution MRI and MRS to evaluate therapeutic response to Novo_TTF in brain tumors. | $29,667 | 0 | 1 |
| Pivotal randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gerncitabina and namb/paciltaxel for front-line treatment of locally- advanced pancreatic adenocarcinoma | $27,946 | 0 | 1 |
| Pivotal randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gerncitabina and nab-paciltaxel for front-line treatment of locally- advanced pancreatic adenocarcinoma | $27,946 | 0 | 1 |
| Proposed Pilot Study Of Combined NovoTTF-100A, Bevacizumab, and Hypofractionated Stereotactic Irradiation for Bevacizumab-Naiive, Recurrent Glioblastoma. | $25,981 | 0 | 1 |
| Multimodal Imaging of Metabolic Changes During NovoTTF Treatment in Patient with Recurrent and Newly-Diagnosed Glioblastoma | $25,200 | 0 | 1 |
| Pilot Study of NovoTTF-100A for Recurrent Atypical and Anaplastic Meningioma | $5,000 | 0 | 1 |
| Multimodal Imaging of Metabolic Changes During NovoTTF Treatment in Patient with Recurrent Glioblastoma | $4,095 | 0 | 1 |
| EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC) | $3,300 | 0 | 1 |
| NovoTTF-100A System therapy for refractory CNS involved small cell lung cancer | $500.00 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Radiation Oncology | $620.71 | 7 | $88.67 |
| Specialist | $83.90 | 1 | $83.90 |
| Neurology | $68.65 | 1 | $68.65 |
| Neurological Surgery | $25.11 | 1 | $25.11 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Matthew Ballo, M.d, M.D | Radiation Oncology | Memphis, TN | $148.63 | $0 |
| Daniel Dosoretz, Md, MD | Radiation Oncology | Port Charlotte, FL | $103.60 | $0 |
| Dr. Arie Dosoretz, Md, MD | Radiation Oncology | Fort Myers, FL | $103.60 | $0 |
| Paul Monsour, M.d, M.D | Radiation Oncology | Metairie, LA | $97.10 | $0 |
| Ellen Zakris, Md, MD | Radiation Oncology | New Orleans, LA | $97.10 | $0 |
| Mark Perman, M.d, M.D | Specialist | Stuart, FL | $83.90 | $0 |
| Joachim Baehring, Md, MD | Neurology | New Haven, CT | $68.65 | $0 |
| Volker Stieber, Md, MD | Radiation Oncology | Winston Salem, NC | $48.88 | $0 |
| Dr. Sandeep Mittal, Md Frcsc Facs, MD FRCSC FACS | Neurological Surgery | Roanoke, VA | $25.11 | $0 |
| David Diamond, M.d, M.D | Radiation Oncology | Winter Park, FL | $21.80 | $0 |
Ad
Top Products
- Optune $2.3M
- Oncology $500.72
Payment Categories
- Food & Beverage $798.37
- Research $2.6M
About Novocure Israel Ltd
Novocure Israel Ltd has made $2.9M in payments to 10 healthcare providers, recorded across 79 transactions in the CMS Open Payments database. In 2023, the company paid $138,036. The top product by payment volume is Optune ($2.3M).
Payments were distributed across 4 medical specialties. The top specialty by payment amount is Radiation Oncology ($620.71 to 7 doctors).
Payment categories include: Food & Beverage ($798.37), Research ($2.6M).